Bioora Ltd.

The goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called WZTL-002 is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not responded to or have come back after standard chemotherapy. The main questions this trial aims to answer are:
* What is the likelihood of complete response of the lymphoma after WZTL-002 treatment?
* What is the risk of altered brain function (neurotoxicity) after WZTL-002?
All eligible participants will receive WZTL-002; the researchers will compare the complete response rate and neurotoxicity rate with historical groups of patients who were treated with similar therapies.
Participants will:
* Have a procedure to gather white blood cells
* Receive chemotherapy to prepare for the CAR T-cells
* Receive WZTL-002 CAR T-cells through a vein
* Be monitored closely for the first 14 days for certain side effects
* Have scans 28 days and 3, 6, 12 and 24 months after WZTL-002 CAR T-cells to check if the treatment has worked